Prague-based KAYA VC, which invests in early-stage startups, is raising its fifth fund to support Slovak, Polish, and Czech startups. As of now, the firm manages €300 million in assets and has two unicorns in its portfolio.
- Prague-based KAYA VC, which invests in early-stage startups, is raising its fifth fund, with a target of €80 million. It is a generalist fund that will invest globally, with focus on Slovak, Polish, and Czech startups.
- Founded in 2010, KAYA VC has 40 companies in its portfolio, with the value of their shares reaching €300 million. Notable investments include Jutro Medical, TrueClaim, Yoneda Labs, Sensible Bio, DasLab, Digitoo, and Better Stack.
- Additionally, KAYA’s portfolio includes two unicorns: the Czech online grocer Rohlík and the Polish company Docplanner, a leading global platform for managing healthcare practices and scheduling.
- KAYA expects the investor mix for this fifth fund to be similar to the previous one, with most funding coming from institutional investors and about three-quarters from the private sector. The minimum investment with KAYA is €1 million.
"Maintaining consistently high returns across funds and ensuring continuous monetization are crucial for us and our relationship with investors. Our investor base includes successful Central European entrepreneurs, founders of startups we've previously supported, international funds, well-known institutions, and regional banks. Although the typical life cycle of a VC fund exceeds ten years, we anticipate attractive, above-average returns from our first three funds," General Partner at KAYA VC, Tomáš Pačinda, stated in a press release.
